超百億美元將從蘋果流入英偉達
英偉達強勁的走勢獲得了基金公司更多的青睞。股票型基金“科技行業精選指數ETF”(XLK)將在本週五後迎來季度權重調整。SPDR Americas Research主管Matthew Bartolini吿訴媒體,新的比例顯示,微軟仍將是首選股票,其次是英偉達,再然後是蘋果。目前,微軟和蘋果原來各佔XLK約22%的權重,英偉達為6%;根據Bartolini的説法,在週五調整後,英偉達將和微軟各佔21%,蘋果則只有4.5%左右。對於英偉達來説,15%的變化意味着基金將增持其逾100億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.